» Articles » PMID: 24156927

Central European BRCA2 Mutation Carriers: Birth Cohort Status Correlates with Onset of Breast Cancer

Overview
Journal Maturitas
Specialty Geriatrics
Date 2013 Oct 26
PMID 24156927
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Mutations in brca1 and 2 genes lead to a significant increase in the lifetime risk of developing breast (BC) and ovarian cancer (OC). There are indications that birth cohort can influence the cancer risk in brca1 mutation carriers. Therefore, we investigated the risks for BC and OC associated with brca2 mutations in a cohort of female mutation carriers of a genetically heterogeneous Central European population.

Patients And Methods: This study included 246 women in whom a functional mutation in the brca2 gene had been identified at our institution. At the time of analysis, 153 women had developed cancer (142 BC, 9 OC, 2 BC and OC). Risks were estimated using the product limit method. The log rank test was used to compare different strata.

Results: After correction for risk-reducing surgeries, the cumulative risk of developing cancer to age 70 was found to be 88% for BC (95% CI 81-95%) and 31% for OC (95% CI 17-45%). Female brca2 mutation carriers born in 1958 or later were at a significantly higher risk of developing BC at a younger age (p<0.001), while no such age cohort-dependent correlation was found for OC.

Conclusion: The age cohort-dependent early onset in BC in women born after 1958 strongly suggests the importance of exogenous factors such as lifestyle modification while this does not seem to be the case for OC. Female brca2 mutation carriers should be counseled about their age cohort-dependent breast cancer risk.

Citing Articles

Increased prevalence of the founder BRCA1 c.5309G>T and recurrent BRCA2 c.1310_1313delAAGA mutations in breast cancer families from Northerstern region of Morocco: evidence of geographical specificity and high relevance for genetic counseling.

Melki R, Melloul M, Aissaoui S, El Harroudi T, Boukhatem N BMC Cancer. 2023; 23(1):339.

PMID: 37055759 PMC: 10099884. DOI: 10.1186/s12885-023-10822-5.


Spectrum of High-Risk Mutations among Breast Cancer Patients Referred for Multigene Panel Testing in a Romanian Population.

Goidescu I, Nemeti G, Surcel M, Caracostea G, Florian A, Cruciat G Cancers (Basel). 2023; 15(6).

PMID: 36980780 PMC: 10047778. DOI: 10.3390/cancers15061895.


The Importance of Extended Analysis Using Current Molecular Genetic Methods Based on the Example of a Cohort of 228 Patients with Hereditary Breast and Ovarian Cancer Syndrome.

Resch L, Hotz A, Zimmer A, Komlosi K, Singh N, Tzschach A Genes (Basel). 2021; 12(10).

PMID: 34680878 PMC: 8535571. DOI: 10.3390/genes12101483.


Screening of BRCA1/2 genes mutations and copy number variations in patients with high risk for hereditary breast and ovarian cancer syndrome (HBOC).

El Ansari F, Jouali F, Marchoudi N, Bennani M, Ghailani N, Barakat A BMC Cancer. 2020; 20(1):747.

PMID: 32778078 PMC: 7418307. DOI: 10.1186/s12885-020-07250-0.


Pathogenic variant burden in the ExAC database: an empirical approach to evaluating population data for clinical variant interpretation.

Kobayashi Y, Yang S, Nykamp K, Garcia J, Lincoln S, Topper S Genome Med. 2017; 9(1):13.

PMID: 28166811 PMC: 5295186. DOI: 10.1186/s13073-017-0403-7.